Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The "Global Urinary Incontinence Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The Global Urinary Incontinence Therapeutics Market is projected to grow at a CAGR of 3.12% during the period 2019-2023.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend affecting this market is the shift toward novel formulations. Many novel formulations are being developed for the treatment of urinary incontinence and they include the transdermal therapies and mechanism-of-action (MoA)-based therapies such as bete-3- adrenergic agonists and M3 specific anticholinergics.

According to the report, one driver influencing this market is the robust pipeline for the development of drugs for urinary incontinence treatment. Most of the urinary incontinence therapeutics that are currently in Phase III stage are likely to get approved during the forecast period to augment the growth of the global urinary incontinence market. Furthermore, the increasing number of molecules being developed for urinary incontinence treatment will drive the demand for urinary incontinence therapeutics across the period of forecast.

Further, the report states that one challenge affecting this market is the patent expiries of drugs. Since generic drugs are copies of branded drugs, they can be independently developed only after the expiry of patents of the original products which may impede the growth of the market.

Key Vendors

• Allergan
• Astellas Pharma
• Merck
• Novartis
• Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Anticholinergic drugs - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Astellas Pharma
• Merck
• Novartis
• Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/2hb8rx/urinary?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Urological Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.